This work provides evidence for a “butyrate-IDO1-ILA” axis as a potential target of TCM in NASH, highlighting the modulation of gut microbiota-host interactions as a promising therapeutic strategy. The gene discussed is TNFRSF9; the disease is metabolic dysfunction-associated steatohepatitis.